Maravai LifeSciences (NASDAQ: MRVI) reported Q2 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $47.4 million versus the consensus estimate of $47.61 million.

Revenue Guidance for Full Year 2025

With the Chief Executive Officer and Chief Financial Officer transition, Maravai is withdrawing and suspending revenue guidance for 2025. The new leadership team is in the midst of a comprehensive business review and forecasting process and will look to reinstate guidance once that process is complete.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.